Company Overview and News
2018-09-25 seekingalpha - 2
After writing my first three articles, on Conrad Industries and Friedman Industries, I’ve been wondering what stock I wanted to discuss next. I favor writing about a stocks I own. However, most of them have already been discussed extensively and satisfactory on SA. I therefore plan to update you every quarter on my value portfolio as a whole. With this approach I can give readers insight in how my holdings are (under)performing.
EVC XKE AGX CRWS CNRD GME BBED CSS CKX ARG NTIP CATO CBK FRD
2018-08-16 seekingalpha - 13
Fairfax Financial’s largest three stakes are BlackBerry, Resolute Forest Products, and Kennedy Wilson. They together account for ~57% of the 13F assets.
SSYS AP FRFHF CRAY PKX MLUSG RAIL SBNY GE KWN.CL USGPF RFP MDR SSWN BBRY IPI JNJ NTES BB SSWA MCDFF AGX SSW CTL KW RFP KWN ICD GM USG IBM GEC BB CRR ARG HP FLR GNE CBI
2018-05-17 seekingalpha - 9
Fairfax Financial’s largest five stakes are BlackBerry, Resolute Forest Products, Kennedy-Wilson, USG, and Intrepid Potash. They together account for ~85% of the US long assets.
SSYS PGH AP FRFHF CRAY PKX MLUSG RAIL NWPX SBNY GE USGPF KWN.CL RFP MDR SSWN BBRY BRK.A IPI ATUSF JNJ NTES BB SSWA MCDFF GRVVF WFCNP AGX SSW KLIC CHRRF PRAGY CTL XCOOQ KW RFP KWN JEC XCOO USG IBM WFC GEC DEST BB XCO CRR ARG HP RPXC FLR GNE
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EPA:ARG / ARGAN on message board site Silicon Investor.